Issue 3, 2016

In silico-driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors

Abstract

Indoleamine 2,3-dioxygenase is involved in pathological immune escape and has recently become an attractive target for anti-cancer therapy. 4-Phenylimidazole (4-PI) provides a promising starting point for the development of IDO1 inhibitors. With the aim of discovering more potent ligands, a virtual library of imidazoles synthesizable via the van Leusen multicomponent reaction was created and filtered to afford a set of 4,5- and 1,5-disubstituted imidazoles as virtual lead candidates. The compounds were selected according to their docking score and to their synthetic feasibility, synthesized and biologically evaluated. This experimental approach yielded IDO1 inhibitors with an enhanced potency compared to 4-PI; the most active compounds displayed a low micromolar potency, both in enzymatic and cellular assays, while showing no detectable cellular toxicity. A 3D quantitative structure–activity relationship based on the electrostatic and steric ligand–protein interactions was observed.

Graphical abstract: In silico-driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors

Supplementary files

Article information

Article type
Research Article
Submitted
31 Jul 2015
Accepted
02 Oct 2015
First published
08 Oct 2015

Med. Chem. Commun., 2016,7, 409-419

In silico-driven multicomponent synthesis of 4,5- and 1,5-disubstituted imidazoles as indoleamine 2,3-dioxygenase inhibitors

S. Fallarini, A. Massarotti, A. Gesù, S. Giovarruscio, G. Coda Zabetta, R. Bergo, B. Giannelli, A. Brunco, G. Lombardi, G. Sorba and T. Pirali, Med. Chem. Commun., 2016, 7, 409 DOI: 10.1039/C5MD00317B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements